Skip to main content

This website uses cookies. By continuing to use this website, you consent to our use of these cookies. Read more about our use of cookies.

I agree

Main navigation (without target group)

About Sobi
Countries and Products
- United States
- Canada
Investigator Sponsored Studies
News
Careers
Contact Us

Breadcrumb

Home
News archive

Data presented at ASH support emapalumab as an innovative, targeted therapeutic option for primary HLH

Please read more on www.sobi.com.

Footer Menu

Cookies
Terms of use

Copyright Notice: © Sobi, Inc. 2018

This site contains medical information that is intended for residents of the United States and Canada only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy

Sobi United States
+1 781-786-7370
890 Winter Street
Waltham, MA 02451, USA

Sobi Canada
+1 289-291-3852
1155 North Service Rd. West, Unit #11,
Oakville, Ontario, Canada L6M 3E3